Cargando…
Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?
OBJECTIVE: To compare sustained viral response to sofosbuvir/ribavirin ±interferon therapy in patients of hepatitis C with and without liver cirrhosis. METHODS: This observational study of chronic hepatitis C patients was carried out at Doctors Hospital and Medical Center (DH&MC). After diagnost...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368326/ https://www.ncbi.nlm.nih.gov/pubmed/28367169 http://dx.doi.org/10.12669/pjms.331.12163 |
_version_ | 1782517908333658112 |
---|---|
author | Sarwar, Shahid Khan, Anwaar A. |
author_facet | Sarwar, Shahid Khan, Anwaar A. |
author_sort | Sarwar, Shahid |
collection | PubMed |
description | OBJECTIVE: To compare sustained viral response to sofosbuvir/ribavirin ±interferon therapy in patients of hepatitis C with and without liver cirrhosis. METHODS: This observational study of chronic hepatitis C patients was carried out at Doctors Hospital and Medical Center (DH&MC). After diagnostic workup, Sofosbuvir/ribavirin for 24 weeks or sofosbuvir/ribavirin/pegylated interferon for 12 weeks were prescribed. Primary outcome was negative HCV RNA by PCR 12 weeks after treatment completion (SVR(12)). Chi square χ(2) and student’s t test were used to analyze data. RESULTS: Of 216 patients included, liver cirrhosis was present in 112 (51.9%) patients and 69(31.9%) were treatment experienced. Liver disease was decompensated in 37 (17.1%) patients. Of 206 patient who completed study protocol, 173(83.1%) achieved SVR(12), 89.2% (25/28) with triple therapy and 82.2% (148/180) with sofosbuvir/ribavirin therapy. Treatment response was similar between treatment naïve 86.2% (119/138) and treatment experienced 79.4% (54/68) patents. (p value 0.19) SVR(12) was inferior in cirrhosis patients 75.4% (80/106) as compared to those with no cirrhosis 93% (93/100) (p value < 0.000). It was even lesser in those with decompensated liver disease 68.8% (24/35) (p value < 0.000). CONCLUSION: Treatment outcome with sofosbuvir/ribavirin combination therapy in cirrhosis patients is suboptimal especially in those with decompensation as compared to patients without liver cirrhosis. |
format | Online Article Text |
id | pubmed-5368326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Professional Medical Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-53683262017-03-31 Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? Sarwar, Shahid Khan, Anwaar A. Pak J Med Sci Original Article OBJECTIVE: To compare sustained viral response to sofosbuvir/ribavirin ±interferon therapy in patients of hepatitis C with and without liver cirrhosis. METHODS: This observational study of chronic hepatitis C patients was carried out at Doctors Hospital and Medical Center (DH&MC). After diagnostic workup, Sofosbuvir/ribavirin for 24 weeks or sofosbuvir/ribavirin/pegylated interferon for 12 weeks were prescribed. Primary outcome was negative HCV RNA by PCR 12 weeks after treatment completion (SVR(12)). Chi square χ(2) and student’s t test were used to analyze data. RESULTS: Of 216 patients included, liver cirrhosis was present in 112 (51.9%) patients and 69(31.9%) were treatment experienced. Liver disease was decompensated in 37 (17.1%) patients. Of 206 patient who completed study protocol, 173(83.1%) achieved SVR(12), 89.2% (25/28) with triple therapy and 82.2% (148/180) with sofosbuvir/ribavirin therapy. Treatment response was similar between treatment naïve 86.2% (119/138) and treatment experienced 79.4% (54/68) patents. (p value 0.19) SVR(12) was inferior in cirrhosis patients 75.4% (80/106) as compared to those with no cirrhosis 93% (93/100) (p value < 0.000). It was even lesser in those with decompensated liver disease 68.8% (24/35) (p value < 0.000). CONCLUSION: Treatment outcome with sofosbuvir/ribavirin combination therapy in cirrhosis patients is suboptimal especially in those with decompensation as compared to patients without liver cirrhosis. Professional Medical Publications 2017 /pmc/articles/PMC5368326/ /pubmed/28367169 http://dx.doi.org/10.12669/pjms.331.12163 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Sarwar, Shahid Khan, Anwaar A. Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? |
title | Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? |
title_full | Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? |
title_fullStr | Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? |
title_full_unstemmed | Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? |
title_short | Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference? |
title_sort | sofosbuvir based therapy in hepatitis c patients with and without cirrhosis: is there difference? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368326/ https://www.ncbi.nlm.nih.gov/pubmed/28367169 http://dx.doi.org/10.12669/pjms.331.12163 |
work_keys_str_mv | AT sarwarshahid sofosbuvirbasedtherapyinhepatitiscpatientswithandwithoutcirrhosisistheredifference AT khananwaara sofosbuvirbasedtherapyinhepatitiscpatientswithandwithoutcirrhosisistheredifference |